Generic semaglutide is on sale in Canada and India. Can you use it in the US?
Canada and India now sell generic semaglutide, but the FDA has approved none for sale in the United States, and the drug-substance patent it lists runs to December 5, 2031.
Generic semaglutide is approved in India (launched March 21, 2026) and Canada (first Health Canada authorization April 28, 2026), but as of November 9, 2026 none is FDA-approved for US sale. FDA says a drug approved abroad but unapproved here is illegal to import. Your lawful self-pay floor is still brand Wegovy or compounded semaglutide.
What was approved abroad, and when?
India came first. Novo Nordisk's Indian semaglutide patent expired on March 20, 2026, Business Today reported that day. On March 21, Dr. Reddy's Laboratories announced Obeda, which it called India's first DCGI-approved semaglutide injection, for type 2 diabetes. Its stated cost to patients: ₹4,200 a month for either the 2 mg or the 4 mg pen.
Canada followed, and its dates are on the public record:
- April 28, 2026: Health Canada authorized Dr. Reddy's generic semaglutide injection, a generic of Ozempic, for adults with type 2 diabetes. Health Canada called Canada the first G7 country to approve a generic semaglutide. Dr. Reddy's announced the approval on April 29.
- May 1, 2026: Apotex announced Health Canada approval of Apo-Semaglutide Injection, another Ozempic generic for type 2 diabetes.
- Mid-May 2026: Apotex said on May 14 that initial inventory was shipping to wholesalers. Dr. Reddy's announced its Canadian launch in a release dated May 16, saying it launched "within days" of approval.
- June 29–30, 2026: Health Canada approved Apotex's Sevmia, a generic of Wegovy for chronic weight management. It was the third generic semaglutide Health Canada had authorized, with six more submissions under review.
- September 18, 2026: Sandoz announced Health Canada approval of Sandoz Semaglutide, an Ozempic generic for type 2 diabetes. Sandoz said it foresees "no material contribution this year" from any generic semaglutide launch.
Two details matter if you live in the US. Most of these approvals cover type 2 diabetes, not weight management; Sevmia is the exception. And none of the Canadian approval or launch releases we read says anything about selling these products in the United States.
Prices are thin on the ground, too. Health Canada says many generics in Canada cost 45% to 90% less than the brand, but none of the Canadian releases we read printed a price.
Why can't these generics be sold in the US?
Patents. The FDA's Orange Book lists US Patent 8,129,343, a drug-substance patent on Ozempic, with an expiration date of December 5, 2031. A second drug-substance patent listed there, 8,536,122, carried a March 20, 2026 expiration date, but the later patent still stands.
The FDA has already reviewed at least one generic. Apotex says it received the first FDA tentative approval for a generic Ozempic in April 2026, and that the product "is expected to launch once final FDA approval is granted following patent expiration in 2032." A tentative approval is not permission to sell.
So the realistic window for a true US generic is the early 2030s, not 2026. If a seller tells you its semaglutide is an FDA-approved generic, ask for the application number and check it with the FDA before you pay.
Can you import generic semaglutide for personal use?
Generally, no. FDA's personal importation page says: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use." It adds: "If a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import."
That second sentence describes an Indian or Canadian generic exactly. A DCGI or Health Canada approval does not make a product FDA-approved.
FDA does describe limited enforcement discretion. Its conditions include a serious condition "for which effective treatment may not be available domestically," "no known commercialization or promotion of the product to persons residing in the U.S.," and generally no more than a three-month supply. FDA-approved semaglutide is sold here, and a website advertising to Americans is promotion to US residents. Those sales are hard to fit inside the policy.
Enforcement is not hypothetical. In September 2026 FDA sent warning letters to two internet pharmacies over unapproved injectable semaglutide sold as "Semanat" (letter 737806, dated September 23) and "Semanext" (letter 737810, dated September 24). Our warning-letter tracker covers them in detail.
How do "generic semaglutide" sellers use the foreign launches?
The Canadian and Indian news gives these sites a true headline to borrow. The move to watch is the jump from "a generic was approved somewhere" to "you can buy it here." Look for:
- Borrowed approvals. "Health Canada approved" or "DCGI approved" printed beside a checkout that ships to US addresses. Those approvals stop at the border.
- No prescription. FDA's letter to onlinegenericmedicine.com cited offering semaglutide "without requiring a prescription" as a reason the product was misbranded.
- Brand names with no US application. FDA's letters say no approved drug application is in effect for products like Semanat and Semanext.
- Foreign prices as bait. Obeda's ₹4,200 monthly price is real, but it is the price of a product approved for patients in India.
- "Generic" used for compounded drugs. Some US sellers call compounded semaglutide "generic." It is not. Compounded semaglutide is made with the drug in Wegovy and Ozempic, but it is not the same product, it is not FDA-approved and it is not a generic.
FDA's letter warns that unapproved drugs "may be contaminated, counterfeit" or contain different ingredients. For packaging and label checks, see our guide to spotting counterfeit GLP-1s. This page is about the legal route and the price you pay on it.
What is the lawful US self-pay floor today?
In the US, your realistic options are brand semaglutide from Novo Nordisk's NovoCare pharmacy, Medicare's GLP-1 Bridge if you qualify, or compounded semaglutide prescribed by a licensed clinician and filled by a state-licensed pharmacy. FDA's own advice is to buy only from state-licensed pharmacies. The table uses each seller's own price page.
| Option | What the price covers | Monthly price (USD) | 12-month cost (USD) | Price read |
|---|---|---|---|---|
| Medicare GLP-1 Bridge | $50 copay for Wegovy (pen or pill), Foundayo or Zepbound KwikPen; eligible Part D enrollees only, through Dec 31, 2027 | 50 | 600 | Nov 9, 2026 |
| Wegovy pill, NovoCare | 1.5 mg dose (FDA-approved) | 149 | 1,788 | Oct 15, 2026; rechecked Nov 9 |
| Wegovy pill, NovoCare | 9 mg or 25 mg (FDA-approved) | 299 | 3,588 | Oct 15, 2026; rechecked Nov 9 |
| Wegovy pen, NovoCare | 0.25 to 2.4 mg (FDA-approved); new patients pay $199 for two 0.25/0.5 mg fills through Dec 31, 2026 | 349 | 4,188 | Oct 15, 2026; rechecked Nov 9 |
| Collective (compounded) | Same price at all doses, plus a $199 annual membership | 59 + 199 a year | 907 | Oct 15, 2026 |
| Mondae (compounded) | Month to month; $75 and $69 a month on prepaid 3- and 6-month terms | 87 | 1,044 | Oct 15, 2026 |
| Eden Health (compounded) | Same price at all doses, no membership | 99 | 1,188 | Oct 15, 2026 |
| NexLife (compounded) | Month to month, same price at every dose, no membership; $95 a month on the 12-month plan ($1,140) | 109 | 1,308 | As of Nov 6, 2026 |
NexLife charges $109 a month for compounded semaglutide month to month, or $105, $99 and $95 a month on 3-, 6- and 12-month plans (as of November 6, 2026), the same at every dose, with no membership fee. Its plan pages name three state-licensed 503A pharmacies. Compounded semaglutide is not FDA-approved.
Read the table as a floor, not a ranking. The NovoCare and Medicare rows are FDA-approved products. The compounded rows cost less, but compounded semaglutide is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness or quality before they are sold. Our compounding legality guide explains the rules those pharmacies work under.
Three programs in the table price below NexLife's $109 month-to-month rate: Collective, Mondae and Eden Health. We list them as published. More programs, including "as low as" offers we do not annualize, are in our GLP-1 pricing database.
What this means for you
If you are on Medicare Part D and qualify for the Bridge: 12 × $50 = $600 a year, against 12 × $349 = $4,188 for the Wegovy pen at NovoCare's self-pay price. That is $3,588 less. Medicare.gov says people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan "might cover" a GLP-1. Our Medicare GLP-1 guide walks through the rules.
If you pay cash for FDA-approved semaglutide: the pill at 25 mg costs 12 × $299 = $3,588 a year, and the pen at 2.4 mg costs $4,188. The gap is $600 a year. Our Wegovy cost guide covers the dose-by-dose prices.
If you are weighing compounded against brand: Eden Health's $99 flat price comes to $1,188 a year, $3,000 less than the Wegovy pen. Collective's $59 plus its $199 annual membership comes to $907, about $75.58 a month. NexLife's 12-month plan works out to 12 × $95 = $1,140.
If a website offers you Canadian or Indian generic semaglutide: there is no lawful US price to compare it with. You would be paying for a product FDA says is illegal to import, bought outside the state-licensed pharmacies FDA tells consumers to use.
What should you watch for next?
In Canada, Health Canada said on June 29 that six more generic submissions were under review, and Sandoz has not given a launch date. In the US, the dates to watch are the 2031 patent expiry in the Orange Book and Apotex's stated 2032 launch plan. Neither date moves because Canada or India approved a generic. We keep a running log on our generic semaglutide abroad news page.
Frequently asked questions
Is generic semaglutide approved in the United States?
Not for sale. Apotex says it received the first FDA tentative approval for a generic Ozempic in April 2026, but it expects to launch only after final approval following patent expiration in 2032. FDA's Orange Book lists a semaglutide drug-substance patent expiring December 5, 2031. Until then, Wegovy and Ozempic are sold in the US only as brand products.
Can I order Canadian generic semaglutide with my US prescription?
A US prescription does not change the import rule. FDA's personal importation page says a drug approved in another country but unapproved in the US is illegal to import. Its enforcement discretion is narrow and generally excludes products promoted to US residents or available here. Canadian generics, including Sevmia, are approved by Health Canada, not FDA.
Is compounded semaglutide the same as generic semaglutide?
No. A generic is reviewed and approved by FDA against a brand drug. Compounded semaglutide is made with the drug in Wegovy and Ozempic by a pharmacy, but it is not the same product, it is not FDA-approved and it is not a generic. Sellers who call compounded semaglutide "generic" are using the word loosely.
When could a real US generic arrive?
Early 2030s, based on the records we read. FDA's Orange Book lists US Patent 8,129,343 for Ozempic as expiring December 5, 2031, and Apotex says its tentatively approved generic is expected to launch after patent expiration in 2032. Treat any earlier date a seller quotes as unconfirmed until FDA grants final approval.
What are the lawful lower-cost ways to get semaglutide in the US?
If you qualify for Medicare's GLP-1 Bridge, the copay is $50 a month through December 31, 2027. NovoCare sells the Wegovy pill from $149 a month at 1.5 mg and the pen at $349. Compounded examples in our dataset include Collective at $59 a month plus a $199 annual membership ($907 a year) and Eden Health at $99 a month (both read October 15, 2026), though compounded drugs are not FDA-approved.
Sources
- Health Canada — Canada becomes the first G7 country to approve a generic version of semaglutide (Published 2026-04-28; read 2026-11-09)
- Health Canada — Canada approves first generic semaglutide for weight loss (Published 2026-06-29; read 2026-11-09)
- Apotex — Health Canada approval of Apo-Semaglutide Injection (generic equivalent of Ozempic) (Published 2026-05-01; read 2026-11-09)
- Apotex — Apo-Semaglutide Injection launch in Canada (Published 2026-05-14; read 2026-11-09)
- Apotex — Health Canada approval of SEVMIA (generic semaglutide for chronic weight management) (Published 2026-06-30; read 2026-11-09)
- Apotex — First Quarter 2027 results (US FDA tentative approval; launch after patent expiration in 2032) (Published 2026-08-12; read 2026-11-09)
- Dr. Reddy's Laboratories — Launches its generic Semaglutide Injection in Canada (Business Wire release, syndicated copy) (Published 2026-05-16; read 2026-11-09)
- Dr. Reddy's Laboratories — Health Canada notice of compliance announcement (PTI report) (Published 2026-04-29; read 2026-11-09)
- Dr. Reddy's Laboratories — Launch of DCGI-approved semaglutide injection Obeda in India (company release as reported by BioSpectrum India) (Published 2026-03-21; read 2026-11-09)
- Business Today — Semaglutide's patent expired in India on March 20, 2026 (Published 2026-03-20; read 2026-11-09)
- Sandoz — Regulatory approval for generic semaglutide in Canada (EQS release) (Published 2026-09-18; read 2026-11-09)
- FDA Orange Book — Patent and exclusivity data, Ozempic (NDA 209637) (Read 2026-11-09)
- FDA — Personal Importation (Content current as of 2025-08-18; read 2026-11-09)
- FDA warning letter 737806 — Online Generic Medicine (onlinegenericmedicine.com) (Dated 2026-09-23; read 2026-11-09)
- FDA warning letter 737810 — Cheap Medicine Shop (cheapmedicineshop.com) (Dated 2026-09-24; read 2026-11-09)
- FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (Content current as of 2026-10-01; read 2026-11-09)
- NovoCare — Wegovy self-pay offer (pen and pill prices) (Read 2026-10-15; rechecked 2026-11-09)
- Medicare.gov — Medicare GLP-1 Bridge (Read 2026-11-09)
- Collective — Holistic weight loss pricing (Read 2026-10-15)
- Mondae — Compounded semaglutide pricing (Read 2026-10-15)
- Eden Health — GLP-1 treatments pricing (Read 2026-10-15)
- NexLife — Semaglutide plans (Prices as of 2026-11-06)